Fenchem Preparing for Hyamax ClinicalFenchem Preparing for Hyamax Clinical
July 24, 2006
NANJING, China—Fenchem Enterprises (www.fenchem.com) is preparing a protocol for clinical tests in animals and humans on the impact of its Hyamax™ sodium hyaluronate (HA) at different molecular weights. According to Fenchem, the study is designed to compare distribution and metabolism of HA with different molecular weights to determine the best weight for maximum absorption and efficiency for joint health. Hyamax is produced through microbial fermentation and is available in molecular weights from 8,000 to 3 million Da (Daltons).
You May Also Like
CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claimsSep 22, 2023
Collagen peptide ingredient solutions for seniors’ changing needs – infographicSep 19, 2023
Radicle Insights—Covid Eris and dietary supplements: separating fact from fictionSep 21, 2023
More bioavailable hyaluronic acid complex for today’s beauty-from-within consumer – snapshotSep 18, 2023